SCHEMBL2867558

SCHEMBL2867558

O=C(O)C(NC(=O)N1CCN2C(=O)OC(c3ccccc3)(c3ccccc3)C2C1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.65
ADRB2 P07550 1/20 0.60
APLNR P35414 1/20 0.60
GLP1R P43220 1/20 0.60
FFAR4 Q5NUL3 1/20 0.60
GPR119 Q8TDV5 1/20 0.60
RBP4 P02753 2/20 0.40
ATM Q13315 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CACNA2D1 P54289 1/20 0.36
CACNA1B Q00975 1/20 0.36
CACNB1 Q02641 1/20 0.36
CACNA1C Q13936 1/20 0.36
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
EPHX2 P34913 1/20 0.33
HSD11B1 P28845 1/20 0.33
GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2863701 0.90 NPSR1 (0.61) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2860846 0.88 NPSR1 (0.65) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2863986 0.86 NPSR1 (0.66) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2871219 0.83 NPSR1 (0.62) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2867186 0.81 NPSR1 (0.71) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2865932 0.81 NPSR1 (0.59) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2871588 0.80 NPSR1 (0.69) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2865324 0.79 NPSR1 (1.00) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2864534 0.78 NPSR1 (0.82) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2864823 0.77 NPSR1 (0.65) NPSR1ADRB2APLNRGLP1RFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 NPSR1 211/4885ADRB2 449/4885APLNR 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.